InvestorsHub Logo

stockorus

05/19/21 12:25 PM

#166517 RE: stockorus #166507

In the meantime, Leronlimab is sitting in the shelf not given a chance, though as Dr. Lalezari says it is practically unconscionable given the pandemic situation and our CD12 results.



What's striking is how casually the FDA dismisses our subgroup results. 82% mortality improvement for critical patients! That should make anyone sit up and become urgently determined to find out at once whether this is for real or not. The FDA should at once arrange for the larger trial here and now. If this is true, we can't waste one second more for people are dying daily.

Nothing of that sort. Acting very scientific about it. Just doubling-down on their intractable rejection, and asking us to go through months of stagnation to prove ourselves anew. Are they stupid, perhaps? Hey, we are an OTC company, we cannot do the kind of trials like Big Pharma. Can not the govt. agency recognize the incredible "hypothesis" generated from the subgroup and help us in getting through the next phase, at the least?

Nope. Nothing. Do or die yourself, whether your drug really works or not. We don't care. We are too big and perfect.

misiu143

05/19/21 12:31 PM

#166519 RE: stockorus #166507

Stockorus , Yes , this is a really tragic thing in this saga and manipulation..


All IMO.